Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label deucrictibant XR prophylaxis in hereditary angioedema (Japan)
jRCT2061250033Recruiting
- Sponsor
- Pharvaris
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of deucrictibant in hereditary angioedema (HAE), sponsored by Pharvaris. Primary endpoints: Treatment-emergent adverse events, Change in heart rate and 4 more. Started Jul 2025; status: recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2061250033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250033.